>> Did you note the word short in the fifth paragraph of my previous post (#1391)? <<
I did , but I don't think it matters , except possibly in the limited case of pregnant patients , where treatment with Tyzeka would be preferred , even if the intent was to switch to something else after delivery.
You could make the same argument for using lamivudine as first-line , i.e. , what does it hurt to use the cheapest drug first ? For some patients , it works well for quite a while , for the others , just switch them to something else. No worries.
Even a limited period of ineffective tx. could result in generation of resistance mutations that will make subsequent tx. more difficult. Docs won't take that chance knowingly , IMO , at least not in the tort-happy USA.
JMHO.
Market Data 
Markets 
AI
